お知らせ • Mar 25
Mushrooms Inc. Achieves Proof Of Concept For Mycolabx Infection-Detection Technology And Provides Strategic Update
Mushrooms Inc. announced the successful early-stage validation of its mycelium-based infection detection technology and the completion of beta testing for its MycoLab.ai research platform, marking a significant advancement in the development of its MycoLabX platform. Over the past weeks, MycoLabX has achieved an important technical milestone in collaboration with the company’s research team in Germany. Prototype testing successfully demonstrated a visible color-change response when the company’s mycelium-based films were exposed to bacterial activity, confirming the core sensing mechanism underlying the company’s infection-detection biomaterials platform. This milestone represents successful early-stage proof of concept, validating the foundational biological response central to the company’s patent-pending technology. The observed biological response supports the company’s approach, which utilizes engineered mycelium-derived biomaterials designed to react to bacterial presence and provide a visual indication of infection. Following this initial validation, the company is preparing for the next phase of development, which is expected to include expanded testing and third-party validation initiatives, including evaluation pathways with leading U.S. research and defense-related institutions. This successful early validation represents a key milestone toward the development of next-generation biomaterials capable of detecting infection in wound care, medical monitoring, and related healthcare applications. The company believes such technologies may ultimately support future regulatory pathways applicable to biomedical sensing and wound-monitoring devices. The intellectual property covering these technologies is currently under review with the United States Patent and Trademark Office as part of the company’s ongoing patent application process. These developments have contributed to a reassessment of the company’s strategic positioning and the potential value of the MycoLabX platform. Management believes the successful demonstration of this core mechanism, combined with planned next-phase validation, represents a meaningful advancement toward commercialization and significantly enhances the platform’s long-term value potential. These recent scientific developments significantly expand the potential value and strategic direction of the MycoLabX platform and support the company’s continued investment in advancing the technology through additional validation and development phases. In addition, the MycoLab.ai mycology research platform has successfully completed beta testing, demonstrating the effectiveness of its AI-driven interface in accessing and organizing foundational scientific data within the platform. MycoLab.ai is a proprietary, structured research environment focused exclusively on global mycology, designed to enable efficient discovery, analysis, and application of fungal science. The platform incorporates advanced artificial intelligence tools to assist researchers, growers, product developers, and scientists in identifying relevant insights and accelerating the practical application of mycological research. Early testing indicates meaningful improvements in research efficiency and data accessibility compared to traditional methods. MycoLabX combines this proprietary data and AI capability with its broader biomaterials and applied fungal biotechnology initiatives, creating a unified ecosystem intended to support innovation, product development, and commercialization. Management believes this integrated approach positions MycoLabX to participate in multiple high-growth sectors, including healthcare, sustainable materials, agriculture, environmental applications, and industrial biotechnology. Mushrooms Inc. will continue advancing development of the MycoLabX platform, including next phase testing of its infection-detection biomaterials and the launch of the MycoLab.ai research platform. To support these next-stage development activities, the company is actively evaluating strategic funding opportunities to accelerate validation, scale testing, and advance the biomaterials platform toward commercialization. The company believes the recent technical validation and progress within the MycoLabX platform create new opportunities to pursue strategic partnerships, research collaborations, and investment aligned with the expanded potential of the platform. In connection with its continued development and upcoming validation initiatives, the Company is evaluating opportunities to engage with accredited investors interested in participating in the next phase of MycoLabX’s growth. This potential financing is intended to support further product development, scale-up of biomaterials production, and advancement toward clinical and institutional validation, including planned collaboration efforts. Accredited investors who are interested in learning more about this opportunity may request additional information by contacting the Company directly.
